Lara Sullivan
Chief Executive Officer bei PYXIS ONCOLOGY, INC.
Vermögen: 8 Mio $ am 31.03.2024
Profil
Dr. Lara S.
Sullivan is a President, Chief Executive Officer & Director at Pyxis Oncology, Inc. She is on the Board of Directors at Pyxis Oncology, Inc. Dr. Sullivan was previously employed as a President & Director by SpringWorks Therapeutics LLC, a Vice President by Pfizer Inc., and an Associate by McKinsey & Co., Inc. She also served on the board at Rexahn Pharmaceuticals, Inc. She received her undergraduate degree from Cornell University, a graduate degree from Perelman School of Medicine and an MBA from The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC.
3,21% | 26.03.2024 | 1 866 547 ( 3,21% ) | 8 Mio $ | 31.03.2024 |
Aktive Positionen von Lara Sullivan
| Unternehmen | Position | Beginn |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Chief Executive Officer | 11.12.2019 |
Ehemalige bekannte Positionen von Lara Sullivan
| Unternehmen | Position | Ende |
|---|---|---|
SpringWorks Therapeutics LLC
 SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Founder | 01.01.2018 |
| PFIZER, INC. | Corporate Officer/Principal | 01.01.2017 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
| REXAHN PHARMACEUTICALS, INC. | Director/Board Member | - |
Ausbildung von Lara Sullivan
| Cornell University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Perelman School of Medicine | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
SpringWorks Therapeutics LLC
SpringWorks Therapeutics LLC BiotechnologyHealth Technology SpringWorks Therapeutics, Inc. engages in the development of biopharmaceutical products for patients with severe rare diseases and cancer. It focuses in advancing the pipeline of standalone and combination therapies with an initial focus on rare diseases and oncology. The company was founded by Lara S. Sullivan in 2017 and is headquartered in Stamford, CT. | Health Technology |
